145 related articles for article (PubMed ID: 18362220)
1. VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals.
Aklillu E; Leong C; Loebstein R; Halkin H; Gak E
Blood; 2008 Apr; 111(7):3903-4. PubMed ID: 18362220
[No Abstract] [Full Text] [Related]
2. VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy.
Orsi FA; Annichino Bizzacchi JM; de Paula EV; Ozelo MC; Langley MR; Weck KE
Thromb Res; 2010 Sep; 126(3):e206-10. PubMed ID: 20615525
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic.
Shuen AY; Wong BY; Fu L; Selby R; Cole DE
Clin Biochem; 2012 Apr; 45(6):397-401. PubMed ID: 22266406
[TBL] [Abstract][Full Text] [Related]
4. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
[TBL] [Abstract][Full Text] [Related]
5. Exacerbation of hereditary warfarin resistance by azathioprine.
Pushpakom SP; Gambhir N; Latif A; Hadfield KD; Campbell S; Newman WG
Clin Appl Thromb Hemost; 2011 Jun; 17(3):293-6. PubMed ID: 20211925
[TBL] [Abstract][Full Text] [Related]
6. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance.
Loebstein R; Dvoskin I; Halkin H; Vecsler M; Lubetsky A; Rechavi G; Amariglio N; Cohen Y; Ken-Dror G; Almog S; Gak E
Blood; 2007 Mar; 109(6):2477-80. PubMed ID: 17110455
[TBL] [Abstract][Full Text] [Related]
7. Shifting paradigms in the pharmacogenetics of warfarin.
Gak E; Halkin H
Pharmacogenomics; 2008 Oct; 9(10):1373-5. PubMed ID: 18855523
[No Abstract] [Full Text] [Related]
8. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.
Tatarūnas V; Lesauskaitė V; Veikutienė A; Jakuška P; Benetis R
Medicina (Kaunas); 2011; 47(1):25-30. PubMed ID: 21681008
[TBL] [Abstract][Full Text] [Related]
9. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
Scott SA; Edelmann L; Kornreich R; Desnick RJ
Am J Hum Genet; 2008 Feb; 82(2):495-500. PubMed ID: 18252229
[TBL] [Abstract][Full Text] [Related]
10. Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans.
Bodin L; Perdu J; Diry M; Horellou MH; Loriot MA
J Thromb Haemost; 2008 Aug; 6(8):1436-9. PubMed ID: 18532998
[No Abstract] [Full Text] [Related]
11. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1.
Harrington DJ; Underwood S; Morse C; Shearer MJ; Tuddenham EG; Mumford AD
Thromb Haemost; 2005 Jan; 93(1):23-6. PubMed ID: 15630486
[TBL] [Abstract][Full Text] [Related]
12. [Haplogroup analysis of vitamin-K epoxide reductase (VKORC1) gene: novel element in the optimization of anticoagulant therapy].
Sipeky C; Melegh B
Orv Hetil; 2008 Sep; 149(39):1839-44. PubMed ID: 18805772
[TBL] [Abstract][Full Text] [Related]
13. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.
Suriapranata IM; Tjong WY; Wang T; Utama A; Raharjo SB; Yuniadi Y; Tai SS
BMC Med Genet; 2011 Jun; 12():80. PubMed ID: 21639946
[TBL] [Abstract][Full Text] [Related]
14. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.
Yuan HY; Chen JJ; Lee MT; Wung JC; Chen YF; Charng MJ; Lu MJ; Hung CR; Wei CY; Chen CH; Wu JY; Chen YT
Hum Mol Genet; 2005 Jul; 14(13):1745-51. PubMed ID: 15888487
[TBL] [Abstract][Full Text] [Related]
15. Variability in CYP2C9 allele frequency: a pilot study of its predicted impact on warfarin response among healthy South and North Indians.
Nahar R; Deb R; Saxena R; Puri RD; Verma IC
Pharmacol Rep; 2013; 65(1):187-94. PubMed ID: 23563037
[TBL] [Abstract][Full Text] [Related]
16. A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists.
Stepien E; Branicka A; Ciesla-Dul M; Undas A
J Appl Genet; 2009; 50(4):399-403. PubMed ID: 19875892
[TBL] [Abstract][Full Text] [Related]
17. Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population.
Efrati E; Elkin H; Sprecher E; Krivoy N
Curr Drug Saf; 2010 Jul; 5(3):190-3. PubMed ID: 20210733
[TBL] [Abstract][Full Text] [Related]
18. Genetic resistance to warfarin therapy masked by amiodarone in a 2-year-old girl with mitral valve replacement.
Moreau C; Bajolle F; Siguret V; Loriot MA; Bonnet D
J Thromb Haemost; 2013 Mar; 11(3):555-72. PubMed ID: 23241284
[No Abstract] [Full Text] [Related]
19. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.
Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y
J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326
[TBL] [Abstract][Full Text] [Related]
20. Genetics of warfarin response.
Mannucci PM; Spreafico M; Peyvandi F
N Engl J Med; 2008 Jun; 358(25):2743; author reply 2743-4. PubMed ID: 18572453
[No Abstract] [Full Text] [Related]
[Next] [New Search]
